Open Access
Antidepressant-Like Activity and Modulation of Brain Monoaminergic Transmission by Blockade of Anandamide Hydrolysis
Gabriella Gobbi,Francis Rodriguez Bambico,Regina A. Mangieri,Marco Bortolato,Patrizia Campolongo,Tommaso Cassano,Maria Grazia Morgese,Guy Debonnel,Andrea Duranti,A. Tontini,Giorgio Tarzia,Marco Mor,Viviana Trezza,Steven R. Goldberg,Vincenzo Cuomo,Daniele Piomelli +15 more
Reads0
Chats0
TLDR
Gobi et al. as discussed by the authors showed that URB597, a selective inhibitor of the enzyme fatty acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test.Abstract:
This Resource Is a peer-reviewed article by Gobi et al. published in the 2005-12-13 issue of the Proceedings of the National Academy of Sciences. The authors show, quoting from the Abstract: '[how] URB597, a selective inhibitor of the enzyme fatty-acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test... These actions are prevented by the CB1 antagonist rimonabant, are accompanied by increased brain anandamide levels... The findings support a role for anandamide in mood regulation and point to fatty-acid amide hydrolase as a previously uncharacterized target for antidepressant drugs.'read more
Citations
More filters
Journal ArticleDOI
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
TL;DR: A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
Journal Article
New approaches to antidepressant drug discovery : beyond monoamines
Olivier Berton,Eric J. Nestler +1 more
TL;DR: This review summarizes the obstacles that have hindered the development of non-monoamine-based antidepressants, and provides a progress report on some of the most promising current strategies.
Journal ArticleDOI
Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade.
TL;DR: The enormous number of studies to be covered in this review prevented in‐depth discussion of many methodological, pharmacological or neurobiological aspects, so the presentation of data had to be limited to a short and condensed summary of the most relevant findings.
Journal ArticleDOI
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen,Pernelle Kruse Kristensen,Pernelle Kruse Kristensen,Else Marie Bartels,Henning Bliddal,Arne Astrup +5 more
TL;DR: The findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials.
Control of pain initiation by endogenous cannabinoids
TL;DR: In this article, anandamide attenuates the pain behavior produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the central nervous system.
References
More filters
Journal ArticleDOI
Depression: a new animal model sensitive to antidepressant treatments
R D Porsolt,M Le Pichon,M Jalfre +2 more
TL;DR: Results presented below indicate that immobility is reduced by different treatments known to be therapeutic in depression including three drugs, iprindole, mianserin and viloxazine which although clinically active show little or no ‘antidepressant’ activity in the usual animal tests.
Journal ArticleDOI
The tail suspension test: A new method for screening antidepressants in mice
TL;DR: A novel test procedure for antidepressants was designed in which a mouse is suspended by the tail from a lever, the movements of the animal being recorded, and the test can separate the locomotor stimulant doses from antidepressant doses.
Journal ArticleDOI
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
TL;DR: A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
Journal ArticleDOI
The molecular logic of endocannabinoid signalling
TL;DR: The endocannabinoids are a family of lipid messengers that engage the cell surface receptors that are targeted by Δ9-tetrahydrocannabinol, the active principle in marijuana (Cannabis).
Journal ArticleDOI
Role of Endogenous Cannabinoids in Synaptic Signaling
TL;DR: The synthetic pathways of endocannabinoids are discussed, along with the putative mechanisms of their release, uptake, and degradation, and the fine-grain anatomical distribution of the neuronal cannabinoid receptor CB1 is described in most brain areas, emphasizing its general presynaptic localization and role in controlling neurotransmitter release.